Lamotrigine micro-tablet and preparation method thereof
Through micro tablet preparation and preparation technology, the existing lamotrigine tablets cannot meet the problem of individualized medication use in children and the elderly, and achieve accurate medication administration and improve medication compliance and reduce adverse reactions.
Patent Information
- Application Number
- CN202411299856.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2016-06-21
- Publication Date
- 2024-11-29
AI Technical Summary
The existing lamotrigine tablets cannot meet the individualized medication needs of children and the elderly, and conventional dosage forms have poor compliance with these populations, making it impossible to achieve accurate medication and reduce the occurrence of adverse reactions.
Using micro-sheet preparation, small doses of lamotrigine micro-sheets are prepared through special granulation formulas and preparation processes, and the components such as fillers, adhesives, disintegrants and lubricants are used to combine with controlled release coatings. and pH-dependent release mechanisms to form micro-tablet preparations that are easy to swallow and accurately administered, and can be loaded in capsules or used in combination with a drug delivery device.
It has achieved accurate administration of drugs in groups with large metabolic differences, reduced adverse reactions, improved medication compliance and efficacy, and is especially suitable for the elderly and young children, and simplified dose adjustment.
Smart Images

Figure BDA0005047302840000021 
Figure BDA0005047302840000022 
Figure BDA0005047302840000023
Abstract
Description
[0001] This application is a divisional application of the Chinese invention patent application with the application date of June 21, 2016, application number: 201610454283.6, and invention name: "A Lamotrigine Microtablet and Preparation Method Thereof". Technical Field
[0002] The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to a lamotrigine microtablet, and provides a method for preparing the lamotrigine microtablet. Background Art
[0003] Epilepsy is a common chronic recurrent neurological disease caused by multiple causes. It is characterized by recurrent epileptic seizures caused by abnormal discharges of brain neurons. The prevalence rate is 5%. There are currently about 9 million epilepsy patients in my country, with about 400,000 new cases each year. Lamotrigine, whose chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine, is an anti-epileptic drug of the phenyltriazine class. Lamotrigine mainly acts on voltage-dependent sodium channels, has an inhibitory effect on repetitive discharges, and may also act on glutamate-related neurotransmitters. Anti-epileptic drugs that can inhibit glutamate and aspartate can stabilize presynaptic membranes and inhibit the release of glutamate and aspartate. It is mainly used to treat intractable epilepsy. At present, the commonly used lamotrigine tablets in the Chinese market are ordinary tablets, and tablet preparations containing 25mg, 50mg, 100mg, and 150mg of active ingredients have been approved for sale.
[0004] Microtablets refer to miniature tablets with a diameter of 1 to 3 mm that are pressed by a special tablet press. Microtablets are dose-dispersible preparations. After oral administration, microtablets are evenly dispersed in the gastrointestinal tract, reducing irritation to the gastrointestinal tract. The gastrointestinal transport and absorption of drugs are less affected by the gastric emptying rate, so the individual differences are small; the drug release behavior of microtablets is the sum of the drug release behaviors of multiple small units that make up a dose. After oral administration, defects in the preparation process of individual small units will not have a serious impact on the drug release behavior of the overall preparation. For people with large individual differences in drug metabolism, such as the elderly and young children, or for drugs whose dosage needs to be adjusted at any time, microtablets are an ideal dosage form. Patients can count and take microtablets according to individualized medication plans, and the measurement is more accurate. Compared with other multi-unit dosage forms, microtablets have more regular shapes and more uniform sizes. Since microtablets are pressed by fixed molds, they have the characteristics of ordinary tablets. Their tablet weight and size are precisely controllable, and the production reproducibility is good. Each microtablet unit has equal size, the same weight, and the same drug content.
[0005] At present, the oral preparations of lamotrigine on the market are mainly tablets, and all of them are dosage specifications for adults. However, in clinical application, lamotrigine usually needs to be adjusted according to the effect. When lamotrigine is used in children, its dosage needs to be calculated based on the child's kilogram body weight. The existing lamotrigine dosage forms cannot meet the requirements of individualized medication, cannot be conveniently and accurately divided into doses, and cannot achieve precise drug administration. In addition, when taking existing drug dosage forms, due to the large size of the dosage form, the compliance of children, the elderly, and patients who are inconvenient to swallow tablets is poor. Summary of the invention
[0006] In order to overcome the defects of the prior art, the present invention provides a lamotrigine microtablet preparation. Through a special granulation formula and preparation process, the lamotrigine microtablet of the present invention can be accurately administered in small doses, especially for people with large individual metabolic differences, such as the elderly and young children, so that accurate administration can be achieved, thereby ensuring the efficacy of the drug while reducing the occurrence of adverse reactions that may be caused by inaccurate dosage. In addition, for people who have difficulty taking conventional preparations, the microtablet is easy to swallow and can improve the compliance of taking the medicine.
[0007] In order to achieve the above-mentioned purpose of the invention, the present invention provides a lamotrigine micro-tablet preparation, and its prescription raw materials and dosage ratio are as follows:
[0008]
[0009] The lamotrigine microtablet preparation of the present invention, wherein the raw materials and their usage ratios in the microtablet are preferably as follows:
[0010]
[0011] Another preferred formulation of the lamotrigine microtablet preparation of the present invention includes the following raw materials and dosage ratios:
[0012]
[0013]
[0014] The filler is selected from one or more of starch, pregelatinized starch, dextrin, microcrystalline cellulose, and lactose. The binder is selected from one or more of HPMC, povidone, gelatin, poloxamer, microcrystalline cellulose, and polyvinyl pyrrolidone. The lubricant is selected from one or more of magnesium stearate, talc, corn starch, stearic acid, calcium stearate, talc, and calcium behenate. The disintegrant is selected from one or more of cross-linked povidone, sodium carboxymethyl starch, cross-linked sodium carboxymethyl cellulose, effervescent disintegrant, sodium alginate, etc.
[0015] The excipients included in the micro-tablet preparation of the present invention are not limited to the types listed in the content of the invention and the examples, and may also include other pharmaceutical excipients, provided that they do not affect the compression molding of the micro-tablets. For example, a surfactant may also be included, and the surfactant may be selected from: sorbitol, mannitol, sodium lauryl sulfate, fatty alcohol polyoxyethylene ether, alkylphenol polyoxyethylene ether, etc.
[0016] The spatial shape of the microchip can be selected as required in principle. The microchip in the present invention is preferably cylindrical, elliptical or spherical in spatial shape. It is preferably a cylindrical shape with a height and a diameter of 1 to 4 mm. The height and the diameter can be arbitrarily selected as required, such as the height and the diameter can be 1.5 mm, 2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm, etc.
[0017] In the microtablet preparation of the present invention, the surface of the microtablet can also be coated by known methods. For example, the active substance lamotrigine can be controlled (generally delayed) released in an aqueous medium by applying at least one layer of coating. Suitable controlled release coatings contain water-insoluble waxes or polymers, preferably ethylcellulose.
[0018] In addition to water-insoluble polymers, the release rate of the active substance can also be arbitrarily adjusted by using non-release-controlling substances in an amount of preferably up to 30 wt.%., preferably water-soluble polymers such as polyvinylpyrrolidone or water-soluble celluloses, preferably hydroxypropylmethylcellulose or hydroxypropylcellulose, and / or known plasticizers.
[0019] In addition to the controlled release coating, the microtablets of the present invention may also have an additional coating. Thus, a coating containing an active substance may be used from which the active substance can be released in an uncontrolled manner after oral administration.
[0020] In addition to the controllable coating, the microtablet formulation of the present invention may also contain a coating that can dissolve in a pH-dependent manner, for example, to ensure that the microtablet formulation does not dissolve after passing through the stomach and is not released until it reaches the intestine.
[0021] The present invention can also load the described lamotrigine microtablet preparation into capsules to prepare an oral preparation in the form of capsules, wherein the capsules contain a certain number of microtablets of controlled release medicine, and the number of microtablets is determined according to a single release time and the amount of medicine to be released. The number of microtablets in the capsule is preferably enough for a dosage of once or twice daily administration. The advantage of using this dosage form is that the dosage of the active ingredient is subdivided between many directly countable microtablets, but since the dosage has been determined in the capsule, the patient does not need to count tediously.
[0022] The micro-tablet preparation of the present invention can be used alone or in combination with a special drug delivery device such as a drug dispensing device to provide more convenient and accurate drug delivery.
[0023] Another object of the present invention is to provide a method for preparing lamotrigine microtablets, wherein the microtablets can be prepared by fluidized bed top spray granulation, wet granulation, dry granulation or fluidized bed bottom spray granulation.
[0024] For example, when the top spray granulation process is adopted, the preparation method is as follows: lamotrigine and a binder are added to purified water, and stirred to form a clear and transparent solution as a granulation binder solution for standby use; the filler is premixed and then placed in the fluidized bed top spray pot; the fluidized bed is opened for blowing, the atomization pressure and the air volume and inlet temperature are adjusted, and the binder solution is sprayed in for top spray granulation; after the binder solution is sprayed, the particles are taken out and dry granulated; after the obtained dry particles are evenly mixed with the prescribed amount of lubricant, the mixture is transferred to a high-speed rotary tablet press for tableting to obtain finished tablets.
[0025] Alternatively, when a wet granulation process is adopted, the preparation method is as follows: lamotrigine, a filler and a binder are placed in the pot of a wet granulator, and after mixing, purified water is sprayed in for wet granulation, wet granulation, and subsequent drying. After drying, the granules are subjected to dry granulation; after the dry granules are uniformly mixed with a prescribed amount of lubricant, the mixture is transferred to a high-speed rotary tablet press for tableting to obtain finished tablets.
[0026] When the dry granulation process is adopted, the preparation method is as follows: after the main drug lamotrigine and other auxiliary materials except the lubricant are mixed evenly, the mixed material is added to the dry granulator to obtain suitable dry granules; after the granules and the lubricant are evenly mixed, the mixed material is transferred to a high-speed rotary tablet press for tableting to obtain finished tablets. DETAILED DESCRIPTION
[0027] Embodiment 1:
[0028]
[0029]
[0030] The preparation process is as follows: weigh lamotrigine, microcrystalline cellulose 102, lactose Flawlac 100 and sodium carboxymethyl starch and mix them evenly, then add magnesium stearate and mix for 2 to 5 minutes, transfer the mixture to a high-speed rotary tablet press for tableting, and obtain the finished lamotrigine micro-tablets.
[0031] Embodiment 2:
[0032] name Dosage Lamotrigine 2mg Microcrystalline Cellulose 101 9.22mg Lactose granulac200 20mg Sodium carboxymethyl starch 0.66mg Povidone K30 0.66mg Magnesium Stearate 0.44mg
[0033] The preparation process is as follows: povidone K30 is prepared into a 3% to 8% solution, lamotrigine, lactose granulac200 and sodium carboxymethyl starch are placed in the pot of a wet granulator, and after mixing, the paddle is turned on and the povidone K30 solution is sprayed in simultaneously for wet granulation, granulation, and then placed in a fluidized bed for drying. After drying, the granules are dry granulated; after the dry granules are uniformly mixed with the prescribed amount of magnesium stearate, the mixture is transferred to a high-speed rotary tablet press for tableting to obtain finished lamotrigine micro-tablets.
[0034] Embodiment 3:
[0035] name Dosage Lamotrigine 3mg Microcrystalline Cellulose 101 20.5mg Crospovidone 1mg Magnesium Stearate 0.8mg
[0036] Preparation process: After lamotrigine, microcrystalline cellulose 101 and cross-linked polyvinylpyrrolidone are uniformly mixed, the mixture is added to a dry granulator to obtain suitable dry granules; after the granules and magnesium stearate are uniformly mixed, the mixture is transferred to a high-speed rotary tablet press for tableting to obtain finished tablets.
[0037] Example 4
[0038]
[0039] Preparation process: Add lamotrigine and povidone K30 into purified water, stir until a clear and transparent solution is formed as a granulation binder solution for later use; pre-mix microcrystalline cellulose 102 and cross-linked carboxymethyl cellulose sodium and put them into the fluidized bed top spray pot; turn on the fluidized bed blower, adjust the atomization pressure and air volume and inlet temperature, and spray the binder solution for top spray granulation; after the binder solution is sprayed, take out the particles and perform dry granulation; after uniformly mixing the obtained dry particles with the prescribed amount of magnesium stearate, transfer the mixture to a high-speed rotary tablet press for tableting to obtain a finished micro-tablet preparation.
Claims
1. A lamotrigine microtablet, characterized in that The raw materials and their usage ratios in the micro-sheets are as follows:
2. The microchip according to claim 1, characterized in that The raw materials and their usage ratios in the micro-sheets are as follows:
3. The microchip according to claim 1, characterized in that The raw materials and their usage ratios in the micro-sheets are as follows:
4. The microtablet according to any one of claims 1 to 3, wherein the filler is selected from one or more of starch, pregelatinized starch, dextrin, microcrystalline cellulose and lactose.
5. The microtablet according to any one of claims 1 to 4, wherein the binder is selected from one or more of HPMC, povidone, gelatin, poloxamer, microcrystalline cellulose, and polyvinyl pyrrolidone, preferably povidone.
6. The microtablet according to any one of claims 1 to 5, wherein the lubricant is selected from one or more of magnesium stearate, talc, corn starch, stearic acid, calcium stearate, talc, and calcium behenate, preferably magnesium stearate.
7. The microchip according to any one of claims 1 to 6, wherein the microchip is in a cylindrical, elliptical or spherical spatial shape, and the microchip is preferably in a cylindrical shape with a height of 1 to 3 mm and a diameter of 1 to 3 mm.
8. The microtablet according to any one of claims 1 to 7, wherein the microtablet is further coated with one or more functional coating layers.
9. The method for preparing the lamotrigine microtablet according to any one of claims 1 to 8, characterized in that The micro-tablets are prepared by fluidized bed top spray granulation, wet granulation, dry granulation, direct powder tableting or fluidized bed bottom spray granulation.
10. A capsule, characterized in that: The capsule contains the lamotrigine microtablet according to any one of claims 1 to 8.
Citation Information
Cited By
Lamotrigine tablet and preparation method thereof
CN120204148A
